A Bristol Myers (BMY) Squibb treatment of pancreatic cancer was granted FDA orphan designation, according to a post to the agency’s website.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Private Markets: Anthropic projects $70B in revenue in 2028
- Bristol Myers reaches $239M settlement over Otezla, Zeposia, Reuters reports
- How MRK, ABBV, and BMY Could Rescue Investor Portfolios in a Downturn
- 3 Stocks to Sell Now, According to Top-Rated Analysts – November 3, 2025
- Balanced Outlook on Bristol-Myers Squibb: Strong Q3 Performance Amid ADEPT-2 Trial Concerns